Breaking News Instant updates and real-time market news.

OTIC

Otonomy

$17.75

-0.1 (-0.56%)

, IONS

Ionis Pharmaceuticals

$46.27

0.52 (1.14%)

07:34
11/30/16
11/30
07:34
11/30/16
07:34

Otonomy names Kathie Bishop as Chief Scientific Officer

Otonomy (OTIC) announced the appointment of Kathie M. Bishop, Ph.D., as chief scientific officer. Dr. Bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience. At Ionis Pharmaceuticals (IONS), she led translational research and development of programs in the neurology franchise including SPINRAZAa, a treatment for patients with spinal muscular atrophy that is awaiting regulatory approval. Bishop succeeds Carl LeBel, Ph.D., who had previously announced his retirement. She joins Otonomy from Tioga Pharmaceuticals where she served as chief scientific officer since 2015.

OTIC

Otonomy

$17.75

-0.1 (-0.56%)

IONS

Ionis Pharmaceuticals

$46.27

0.52 (1.14%)

  • 30

    Nov

  • 03

    Dec

  • 14

    Dec

OTIC Otonomy
$17.75

-0.1 (-0.56%)

05/10/16
PIPR
05/10/16
NO CHANGE
Target $42
PIPR
Overweight
Piper reiterates Overweight on Otonomy amid today's selloff
Piper Jaffray analyst Joshua Schimmer reiterates an Overweight rating on Otonomy amid today's post-earnings pullback. The denial of a J-code for Otoprio is not notable since it is not the appropriate code for the product, Schimmer tells investors in a research note. The analyst is confident that Otpirio will qualify for a C-code. Otiprio may have off-label use opportunities for which a J code may apply, but these are off-label, he adds. Schimmer keeps a $42 price target for the shares.
05/26/16
WBTH
05/26/16
INITIATION
Target $29
WBTH
Buy
Otonomy initiated with a Buy at WallachBeth
Target $29.
10/14/16
RHCO
10/14/16
NO CHANGE
RHCO
Otonomy named top pick at SunTrust
SunTrust analyst Edward Nash named Otonomy as his top pick. The analyst thinks that the company will benefit from strong uptake of its Otiprio drug over the next one to two quarters during peak season for ear tube surgeries. Additionally, he expects the company to report strong data for trials related to the label expansion of Otiprio and its Meniere's disease program. He keeps a $43 price target and Buy rating on the shares.
IONS Ionis Pharmaceuticals
$46.27

0.52 (1.14%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Ionis drug likely to be approved rapidly, says Wells Fargo
After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.
11/01/16
PIPR
11/01/16
NO CHANGE
PIPR
Overweight
Piper sees thrombosis treatment from Ionis as differentiated
Piper Jaffray analyst Joshua Schimmer believes IONS-FXI is differentiated by its "potential utility in renal impairment, infrequent injections and low risk of bleeding complications." Ionis Pharmaceuticals (IONS) and its partner Bayer (BAYRY) reported positive data from a Phase 2 study of IONS-FXI, an anti-clotting antisense therapeutic which targets Factor 11 to prevent thrombosis, Schimmer tells investors in a research note. He views the recent weakness in Ionis shares as a "compelling buying opportunity" and reiterates an Overweight rating on the name.
11/07/16
PIPR
11/07/16
NO CHANGE
PIPR
Biogen, Ionis get jump start on AveXis, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says that following his upgrade this morning, Biogen (BIIB) and its partner Ionis Pharmaceuticals (IONS) announced that a Phase III study of nusinersen met its primary endpoint. The data look "very good," Schimmer tells investors in a research note. This gives Biogen and Ionis a jump start on rival gene therapy player AveXis for the Type II/III setting, Schimmer tells investors in a research note. If not for competition from AveXis, nusinersen would become a $5B-plus mega-blockbuster by addressing one of the highest unmet needs in pediatric diseases that exists today, the analyst contends. Schimmer believes, however, that AveXis is moving quickly to compete in the market. The analyst still hopes Biogen "will find a way to partner" with AveXis. He still thinks nusinersen, which is now called SPINRAZA, can achieve $1B-$2B-plus in peak annual revenue. Following this morning's upgrade, Schimmer has an Overweight rating on Biogen with a $335 price target.
11/07/16
JPMS
11/07/16
NO CHANGE
JPMS
Neutral
JPMorgan still views Ionis as fairly valued
JPMorgan analyst Jessica Fye believes the data today continue to "derisk and solidify" Spinraza's clinical profile. The analyst, however, thinks it will be difficult to lift the overhang around platelet adverse events. She continues to view Ionis Pharmaceuticals as fairly valued and keeps a Neutral rating on the shares. Ionis is up 18% to $32.10 in afternoon trading.

TODAY'S FREE FLY STORIES

KBR

KBR

$14.05

-1.43 (-9.24%)

18:47
04/28/17
04/28
18:47
04/28/17
18:47
Hot Stocks
KBR issues statement on SFO investigation »

KBR made the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SMMT

Summit Therapeutics

$11.00

-0.4 (-3.51%)

18:32
04/28/17
04/28
18:32
04/28/17
18:32
Hot Stocks
Summit Therapeutics publishes results from CoDIFy trial online »

Summit Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.83

0.85 (3.54%)

18:14
04/28/17
04/28
18:14
04/28/17
18:14
Hot Stocks
Takeda says FDA grants accelerated approval of ALUNBRIG »

Takeda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

18:07
04/28/17
04/28
18:07
04/28/17
18:07
Hot Stocks
FDIC named receiver of First NBC Bank »

First NBC Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGBK

Stonegate Bank

$45.90

-0.52 (-1.12%)

17:47
04/28/17
04/28
17:47
04/28/17
17:47
Earnings
Stonegate Bank reports Q1 non-GAAP EPS 56c, consensus 57c »

Reports Q1 NII $25.89M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PROV

Provident Financial

$19.23

-0.03 (-0.16%)

17:45
04/28/17
04/28
17:45
04/28/17
17:45
Hot Stocks
Provident Financial announces extension of stock repurchase plan »

Provident Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

YGE

Yingli Green Energy

$2.66

-0.03 (-1.12%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Yingli Green Energy files extension for 2016 Form 20-F filing »

Yingli Green Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Breaking Hot Stocks news story on Edgewell Personal Care »

Gabelli raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

AEP

American Electric

$67.83

-0.27 (-0.40%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Hot Stocks
AEP Generation Resources seeks bids for supply of coal »

AEP Generation Resources,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:34
04/28/17
04/28
17:34
04/28/17
17:34
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

HBHC

Hancock Holding

$46.70

-0.5 (-1.06%)

, FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

17:34
04/28/17
04/28
17:34
04/28/17
17:34
Hot Stocks
Whitney to acquire branches, assets, liabilities of First NBC from FDIC »

Hancock Holding Company…

HBHC

Hancock Holding

$46.70

-0.5 (-1.06%)

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TSLA

Tesla

$314.07

5.44 (1.76%)

17:31
04/28/17
04/28
17:31
04/28/17
17:31
Periodicals
Tesla aims to hire engineers from Mexico to work at CA plant, Reuters says »

Tesla is aiming to hire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

LMT

Lockheed Martin

$269.45

-1.69 (-0.62%)

17:22
04/28/17
04/28
17:22
04/28/17
17:22
Hot Stocks
Lockheed Martin awarded $332.1M government contract »

Lockheed Martin, Orlando,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$184.83

1.61 (0.88%)

17:21
04/28/17
04/28
17:21
04/28/17
17:21
Hot Stocks
Boeing awarded $541M government contract modification »

The Boeing Co., Ridley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

WBA

Walgreens Boots Alliance

$86.54

0.65 (0.76%)

, RAD

Rite Aid

$4.00

0.05 (1.27%)

17:20
04/28/17
04/28
17:20
04/28/17
17:20
Periodicals
Walgreens to push regulators over decision on Rite Aid deal, NY Post says »

Walgreens (WBA) will…

WBA

Walgreens Boots Alliance

$86.54

0.65 (0.76%)

RAD

Rite Aid

$4.00

0.05 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$28.99

-0.09 (-0.31%)

17:20
04/28/17
04/28
17:20
04/28/17
17:20
Hot Stocks
General Electric awarded $670.7M government contract »

General Electric, Lynn,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 31

    May

  • 22

    Jun

SIX

Six Flags

$62.61

-0.26 (-0.41%)

17:19
04/28/17
04/28
17:19
04/28/17
17:19
Hot Stocks
Six Flags in agreement to repurchase 5M shares from HP Partners »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 17

    May

  • 18

    May

LMT

Lockheed Martin

$269.45

-1.69 (-0.62%)

17:18
04/28/17
04/28
17:18
04/28/17
17:18
Hot Stocks
Lockheed Martin awarded $1.38B government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SBBP

Strongbridge Biopharma

$4.50

0.05 (1.12%)

17:16
04/28/17
04/28
17:16
04/28/17
17:16
Syndicate
Breaking Syndicate news story on Strongbridge Biopharma »

Strongbridge Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

CYH

Community Health

$8.61

0.18 (2.14%)

17:12
04/28/17
04/28
17:12
04/28/17
17:12
Hot Stocks
Community Health completes divestiture of Anniston, Alabama hospital »

Community Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 06

    Jun

MRUS

Merus

$22.20

-0.14 (-0.63%)

17:07
04/28/17
04/28
17:07
04/28/17
17:07
Earnings
Merus reports Q4 EPS (EUR1.91) vs. (EUR0.77) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

AEZS

Aeterna Zentaris

$3.35

0.3 (9.84%)

17:01
04/28/17
04/28
17:01
04/28/17
17:01
Hot Stocks
Aeterna Zentaris to announces top-line Zoptrex phase 3 results on Monday »

Aeterna Zentaris will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

ANY

Sphere 3D

$0.19

-0.006 (-3.13%)

17:00
04/28/17
04/28
17:00
04/28/17
17:00
Syndicate
Breaking Syndicate news story on Sphere 3D »

Sphere 3D files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

MRUS

Merus

$22.20

-0.14 (-0.63%)

16:56
04/28/17
04/28
16:56
04/28/17
16:56
Hot Stocks
Merus provides anticipated 2017 pipeline milestones »

Merus provided 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.